Two of the most studied healing peptides — but they work through entirely different mechanisms. Here is when to use each, how to dose them, and why most serious users eventually run both.
A 15-amino acid peptide derived from a protein found naturally in gastric juice. Its strongest effects are on tendons, ligaments, the gut lining, and peripheral nerves. It promotes healing by upregulating growth factors and forming new blood vessels. Daily subcutaneous dosing at 200–500 mcg is the most common protocol; injecting near the injury site appears to improve local results.
A synthetic fragment of Thymosin Beta-4, a protein involved in actin regulation and cell migration. TB-500 works systemically — it does not need to be injected at the injury site to be effective. Its strongest applications are skeletal muscle repair, wound healing, and cardiac tissue. Typical protocols run a loading phase (2.5–5 mg twice weekly for 4–6 weeks) followed by a lower maintenance dose.
| BPC-157 | TB-500 | |
|---|---|---|
| Type | Pentadecapeptide (15 amino acids) | Synthetic TB4 fragment (43 amino acids) |
| Mechanism | Upregulates growth factors (EGF, VEGF, FGF), promotes angiogenesis, modulates nitric oxide | Sequesters actin, promotes cell migration, angiogenesis, and tissue regeneration |
| Primary targets | Tendons, ligaments, gut lining, nerves, muscle | Skeletal muscle, cardiac tissue, wounds, systemic healing |
| Typical dose | 200–500 mcg/day | 2–5 mg/week (loading), 2–2.5 mg/week (maintenance) |
| Frequency | Daily (split or single injection) | Once or twice weekly |
| Half-life | ~4 hours | ~8 hours (estimated) |
| Administration | Subcutaneous, intramuscular, oral (limited efficacy) | Subcutaneous, intramuscular |
| Systemic effect | Moderate — strongest near injection site for joint injuries | High — works systemically regardless of injection site |
| Research | Extensive animal studies; no human clinical trials | Some human trial data (cardiac); animal studies for musculoskeletal |
| Typical cycle | 4–12 weeks | 8–16 weeks (loading then maintenance) |
BPC-157 works primarily by upregulating a set of growth factors — EGF, VEGF, and FGF chief among them — that drive tissue regeneration. It also interacts with the nitric oxide system, which partly explains its effects on blood pressure and blood flow. One of its more unusual properties is the ability to accelerate tendon-to-bone healing, making it especially useful after acute ligament or tendon injuries.
TB-500 works through a fundamentally different route. Thymosin Beta-4 (and its fragment TB-500) binds to actin monomers and sequesters them, which stimulates the remodelling of the actin cytoskeleton. This drives cell migration — the process by which repair cells move into damaged tissue. The result is faster wound closure, muscle fibre regeneration, and new blood vessel formation. Because this mechanism is not site-dependent, TB-500 is effective regardless of where it is injected.
Choose BPC-157 for:
Choose TB-500 for:
Because they work through different receptors and pathways, BPC-157 and TB-500 are genuinely complementary. BPC-157 drives local repair of tendon and connective tissue; TB-500 handles systemic cell migration and muscle repair. Running them together during an acute injury phase — the first 4–6 weeks — and then dropping TB-500 to maintenance while continuing BPC-157 is a common and well-regarded approach.
Example loading stack
If you can only run one: use BPC-157 for tendon, ligament, or gut issues; use TB-500 for muscle injuries or when you need systemic recovery and cannot inject near the site. If you are dealing with a significant soft tissue injury and recovery speed matters, the stack outperforms either alone. BPC-157 is also generally easier to dose (smaller volumes, daily) and has a more established user base for joint-specific work.
BPC-157 (Body Protective Compound 157) is a pentadecapeptide — a chain of 15 amino acids — derived from a protein found in gastric juice. It has been studied extensively in animal models for its ability to accelerate healing of tendons, ligaments, muscles, the gut lining, and peripheral nerves. It works primarily by upregulating growth factors and promoting new blood vessel formation (angiogenesis).
TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4 (TB4). It is a 43-amino acid fragment that promotes cell migration, angiogenesis, and tissue regeneration by binding and sequestering actin. It is particularly effective for systemic healing — including skeletal muscle, cardiac tissue, and wound repair — and works regardless of where it is injected.
BPC-157 is generally considered the stronger choice for tendon and ligament injuries, particularly when injected near the site. It directly upregulates growth factors involved in tendon repair (including EGF and FGF). TB-500 also promotes tendon healing but through a different pathway (actin regulation). Many users stack both for tendon injuries and report faster recovery than with either alone.
For skeletal muscle damage, TB-500 has the edge. Its mechanism — actin sequestration and cell migration — is especially suited to muscle fibre repair. BPC-157 also helps with muscle healing but is less targeted than TB-500 in this context.
Yes — and it is one of the most popular healing stacks. The two peptides work through complementary mechanisms and are considered synergistic. A common approach is to run BPC-157 daily at 250–500 mcg alongside TB-500 at 2.5–5mg twice weekly during a loading phase of 4–6 weeks, then reduce TB-500 to maintenance while continuing BPC-157.
For joint and tendon injuries, injecting close to the injury site appears to improve localised results. However, BPC-157 also has systemic effects when injected subcutaneously in any location. For gut healing, oral BPC-157 shows some efficacy in animal studies, though subcutaneous dosing produces more consistent results.
Both peptides have generally favourable safety profiles in animal studies. BPC-157 side effects are rarely reported; some users note mild dizziness or nausea at higher doses. TB-500 is similarly well tolerated; occasional reports include fatigue or mild head rush shortly after injection. Neither has long-term human safety data available.
Log BPC-157 and TB-500 injections separately, set daily reminders, and keep a complete record of dose, site, and timing throughout your recovery.
Start Free Trial